An interventional study of Written Exposure Therapy in PTSD (Childbirth-Related), PTSD - Post Traumatic Stress Disorder and PTSD, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,663 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.
Among the 1,663 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,284th largest by planned enrollment of the 1,490 interventional ones that give a count, is one of 97 that started in 2026, is one of 1,011 with no phase, reaches primary completion later than 204 of the 402 other live ones, and was the 1,660th registered.
2,685 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →340 of the 1,663 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Anthony Vesco · Sites in United States
Ages 8–18
Transcend Therapeutics · Sites in United States
Ages 18+
COMPASS Pathways · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,663 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 132 · Phase 2 234 · Phase 3 95 · Phase 4 90
First in 1991; this study’s year is marked. 97 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 69 across 2,199 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 1,490 interventional studies, 107 across the 165 observational. Of the 1,135 that completed or were terminated, 490 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 1,663 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,268 studies on the registry; 229 are open to participants now.
Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 6 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
154 of the studies in Stress Disorders, Post-Traumatic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT04877093Phase 3Wake Forest University Health SciencesRepurposing Low-Dose Clonidine for PTSD in Veterans | 2027-03-31 |
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT07217795University of Rhode IslandRecovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building | 2026-11 |
| NCT04585685Christal L BadourHealthy Recovery After Trauma Study | 2026-11 |
Add all 154 to your calendar (.ics) → With an account.
Among the 1,663 studies in Stress Disorders, Post-Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this research study, the investigators hope to determine whether Written Exposure Therapy is a feasible intervention for postpartum women experiencing trauma symptoms related to childbirth to complete. Written Exposure Therapy involves five structured psychotherapy sessions that can be conducted over telehealth.
Childbirth-related posttraumatic stress disorder (CB-PTSD) affects approximately one in twenty women after any given childbirth. Postpartum women are faced with unique barriers to accessing and engaging in evidence-based treatment for PTSD. Aside from avoidance, limited time and financial and logistical barriers regarding childcare can make it difficult to engage in long-term therapy or travel to frequent in-person visits. Therefore, postpartum individuals may find a brief telehealth-based intervention, Written Exposure Therapy, to be highly appealing and well-aligned with the demands of postpartum parenting.
Written exposure therapy (WET) is a highly protocolized evidence-based brief psychotherapeutic intervention for the treatment of PTSD that may be promising for women with CB-PTSD. WET consists of 5 treatment sessions. In the first, patients receive brief psychoeducation about PTSD and avoidance as a maladaptive behavior that maintains PTSD symptoms. In each of the five sessions, the patient writes about the same single traumatic event with a focus on feelings and cognitions during the event and how the event has affected their lives. Written exposure therapy can be conducted via telehealth, does not require between-session assignments for patients, is non-inferior to cognitive processing therapy and prolonged exposure therapy, and involves only four total hours of treatment, thus decreasing treatment time by 50-80% compared to other evidence-based psychotherapies for PTSD. This study aims to assess whether postpartum individuals would find such an intervention feasible and be able to maintain engagement to complete the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Written Exposure Therapy
Written exposure therapy (WET) is a highly protocolized evidence-based brief psychotherapeutic intervention for the treatment of post-traumatic stress disorder (PTSD).
Feasibility (retention rate)
Feasibility will be measured retention rate across five Written Exposure Therapy (WET) sessions. Retention rate is defined as the number of participants who complete all five WET sessions divided by the total number of participants who engaged in at least one WET session. A higher value indicates higher retention. We expect at least 75% of enrolled participants will complete treatment once initiated.
Time frame: From date of the first WET session until the date of the fifth WET session, withdrawal from the study, or determination of loss to follow-up, whichever occurs first (estimated average assessment period: 6 weeks).
Feasibility (Engagement rate)
Engagement will be measured as the number of participants who engaged in at least one Written Exposure Therapy session divided by the number of women who enrolled in the study. A higher value indicates higher engagement. We expect at least 75% of enrolled participants will engage in treatment.
Time frame: From the date of enrollment until the date of the first WET session, withdrawal from the study, or determination of loss to follow-up, whichever occurs first (estimated average assessment period: 4 weeks).
Acceptability (Credibility)
Credibility will be measured using the pre-intervention credibility/expectancy questionnaire (CEQ) which assesses patient perception of whether treatment seems logical and useful. Credibility is scored as the sum of the first three scale items on the credibility/expectancy questionnaire. Scores range from 3-27, with higher scores indicating greater credibility.
Time frame: Baseline
Acceptability (Satisfaction)
Satisfaction will be measured as total score on the post-intervention Client Satisfaction Questionnaire-8 (CSQ-8) survey. Scores range from 8-32, with higher numbers indicating greater satisfaction.
Time frame: Study exit survey approximately 4 weeks after final WET session.
Changes in PTSD Symptoms Assessed by the PTSD Checklist for DSM-5
The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Scores range from 0 to 80 and a score at or above 28 is indicative of probable CB-PTSD. A 9 point change represents reliable change.
Time frame: From enrollment to study exit survey approximately 4 weeks after the final written exposure therapy session.
Changes in EPDS Symptoms Assessed by the Edinburgh Postnatal Depression Scale
The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-report questionnaire used during pregnancy and postpartum to screen for perinatal and postpartum depression. Scores range from 0-30 and a score at or above 10 is indicative of a positive screen for perinatal depression. A 4 point change indicates reliable change.
Time frame: From enrollment to study exit survey approximately 4 weeks after the final written exposure therapy session.
Changes in PSS Symptoms Assessed by the Perceived Stress Scale
The Perceived Stress Scale (PSS) is a 10-item self-report questionnaire designed to assess perceptions of recent stress. Scores range from 0 to 40, with higher scores indicating higher perceived stress. A 6 point change indicates reliable change.
Time frame: From enrollment to study exit survey approximately 4 weeks after the final written exposure therapy session.
Plan to share: No — Individual participant data will not be shared due to privacy and confidentiality concerns. Aggregate study results will be made publicly available on ClinicalTrials.gov and through publications.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jul 2027, 17 months after the start.
Of 1,065 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 17 months is below that.
Counting every sponsor, half of 1,093 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
Brigham and Women's Hospital →